Enhancing Blockade of Plasmodium falciparum Erythrocyte Invasion: Assessing Combinations of Antibodies against PfRH5 and Other Merozoite Antigens

PLoS Pathogens

Volumn 8, Issue 11, 2012, Pages

  Williams, Andrew R ^a   Douglas, Alexander D ^a   Miura, Kazutoyo ^b   Illingworth, Joseph J ^a   Choudhary, Prateek ^a   Murungi, Linda M ^a,c   Furze, Julie M ^a   Diouf, Ababacar ^b   Miotto, Olivo ^a,d   Crosnier, Cécile ^e   Wright, Gavin J ^e   Kwiatkowski, Dominic P ^a,e,f   Fairhurst, Rick M ^b   Long, Carole A ^b   Draper, Simon J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d MAHIDOL UNIVERSITY   (Thailand)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MEROZOITE SURFACE PROTEIN 1; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; RETICULOCYTE BINDING PROTEIN HOMOLOGUE 5; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN PURIFICATION; ARTICLE; CELL INVASION; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG POTENTIATION; ERYTHROCYTE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; NONHUMAN; PARASITE CULTIVATION; PARASITE DEVELOPMENT; PHARMACOLOGICAL BLOCKING; PLASMODIUM FALCIPARUM; RABBIT; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CARRIER PROTEINS; ERYTHROCYTES; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MEROZOITES; MICE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

PLASMODIUM FALCIPARUM;

EID: 84870778753     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002991     Document Type: Article

References (53)

1. World Health Organization (2011) World malaria report. World Health Organization, 2011.
2. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, et al. (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413-431.
3. Goodman AL, Draper SJ, (2010) Blood-stage malaria vaccines- recent progress and future challenges. Ann Trop Med Parasitol 104: 189-211.
4. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, et al. (2009) High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 4: e8138.
5. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, et al. (2009) Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4: e5254.
6. Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, et al. (2009) Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16: 963-968.
7. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, et al. (2009) Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 4: e4708.
8. Lyon JA, Angov E, Fay MP, Sullivan JS, Girourd AS, et al. (2008) Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS ONE 3: e2830.
9. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, et al. (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004-1013.
10. Crompton PD, Pierce SK, Miller LH, (2010) Advances and challenges in malaria vaccine development. The Journal of Clinical Investigation 120: 4168-4178.
11. Tham W-H, Healer J, Cowman AF, (2012) Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum. Trends in Parasitology 28: 23-30.
12. Cowman AF, Crabb BS, (2006) Invasion of red blood cells by malaria parasites. Cell 124: 755-766.
13. Stubbs J, Simpson KM, Triglia T, Plouffe D, Tonkin CJ, et al. (2005) Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes. Science 309: 1384-1387.
14. Baum J, Chen L, Healer J, Lopaticki S, Boyle M, et al. (2009) Reticulocyte-binding protein homologue 5- an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum. Int J Parasitol 39: 371-380.
15. Hayton K, Gaur D, Liu A, Takahashi J, Henschen B, et al. (2008) Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasion. Cell Host Microbe 4: 40-51.
16. Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, et al. (2011) Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480: 534-537.
17. Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, et al. (2011) The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2: 601.
18. Volkman SK, Sabeti PC, DeCaprio D, Neafsey DE, Schaffner SF, et al. (2007) A genome-wide map of diversity in Plasmodium falciparum. Nat Genet 39: 113-119.
19. Ferreira MU, Ribeiro WL, Tonon AP, Kawamoto F, Rich SM, (2003) Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. Gene 304: 65-75.
20. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, et al. (2009) Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 1: 2ra5.
21. Remarque EJ, Faber BW, Kocken CH, Thomas AW, (2008) Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24: 74-84.
22. Lopaticki S, Maier AG, Thompson J, Wilson DW, Tham WH, et al. (2011) Reticulocyte and erythrocyte binding-like proteins function cooperatively in invasion of human erythrocytes by malaria parasites. Infect Immun 79: 1107-1117.
23. Arumugam TU, Takeo S, Yamasaki T, Thonkukiatkul A, Miura K, et al. (2011) Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen. Infect Immun 79: 4523-4532.
24. Ord RL, Rodriguez M, Yamasaki T, Takeo S, Tsuboi T, et al. (2012) Targeting Sialic Acid Dependent and Independent Pathways of Invasion in Plasmodium falciparum. PLoS One 7: e30251.
25. Chen L, Lopaticki S, Riglar DT, Dekiwadia C, Uboldi AD, et al. (2011) An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum. PLoS Pathog 7: e1002199.
26. Saul A, Fay MP, (2007) Human Immunity and the Design of Multi-Component, Single Target Vaccines. PLoS One 2: e850.
27. Singh S, Miura K, Zhou H, Muratova O, Keegan B, et al. (2006) Immunity to Recombinant Plasmodium falciparum Merozoite Surface Protein 1 (MSP1): Protection in Aotus nancymai Monkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory Activity. Infection and Immunity 74: 4573-4580.
28. Mahdi Abdel Hamid M, Remarque EJ, van Duivenvoorde LM, van der Werff N, Walraven V, et al. (2011) Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT protects against blood-stage challenge in rhesus macaques. PLoS One 6: e20547.
29. Duncan CJA, Hill AV, Ellis RD, (2012) Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Human Vaccines and Immunotherapeutics 8: 706-714.
30. Duncan CJA, Sheehy SH, Ewer KJ, Douglas AD, Collins KA, et al. (2011) Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One 6: e22271.
31. Pol E, Karlsson R, Roos H, Jansson Å, Xu B, et al. (2007) Biosensor-based characterization of serum antibodies during development of an anti-IgE immunotherapeutic against allergy and asthma. Journal of Molecular Recognition 20: 22-31.
32. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, et al. (2008) Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26: 193-200.
33. Manske M, Miotto O, Campino S, Auburn S, Almagro-Garcia J, et al. (2012) Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature 487: 375-379.
34. Bliss CI, (1939) The Toxicity of Poisons Applied Jointly. Annals of Applied Biology 26: 585-615.
35. Greco WR, Bravo G, Parsons JC, (1995) The Search for Synergy: A critical review from a Response Surface Perspective. Pharmalogical Reviews 47: 337-387.
36. Narum DL, Haynes JD, Fuhrmann S, Moch K, Liang H, et al. (2000) Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun 68: 1964-1966.
37. Faber BW, Remarque EJ, Morgan WD, Kocken CH, Holder AA, et al. (2007) Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infect Immun 75: 5947-5955.
38. Arnot DE, Cavanagh DR, Remarque EJ, Creasey AM, Sowa MP, et al. (2008) Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum. Clin Vaccine Immunol 15: 1345-1355.
39. Miura K, Zhou H, Moretz SE, Diouf A, Thera MA, et al. (2008) Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol 181: 8776-8783.
40. Baum J, Maier AG, Good RT, Simpson KM, Cowman AF, (2005) Invasion by P. falciparum Merozoites Suggests a Hierarchy of Molecular Interactions. PLoS Pathog 1: e37.
41. Riglar DT, Richard D, Wilson DW, Boyle MJ, Dekiwadia C, et al. (2011) Super-resolution dissection of coordinated events during malaria parasite invasion of the human erythrocyte. Cell Host Microbe 9: 9-20.
42. Saul A, (1987) Kinetic constraints on the development of a malaria vaccine. Parasite Immunol 9: 1-9.
43. Bannister LH, Mitchell GH, (2009) The malaria merozoite, forty years on. Parasitology 136: 1435-1444.
44. Singh S, Alam MM, Pal-Bhowmick I, Brzostowski JA, Chitnis CE, (2010) Distinct External Signals Trigger Sequential Release of Apical Organelles during Erythrocyte Invasion by Malaria Parasites. PLoS Pathog 6: e1000746.
45. Triglia T, Thompson J, Caruana SR, Delorenzi M, Speed T, et al. (2001) Identification of proteins from Plasmodium falciparum that are homologous to reticulocyte binding proteins in Plasmodium vivax. Infect Immun 69: 1084-1092.
46. Tham WH, Wilson DW, Reiling L, Chen L, Beeson JG, et al. (2009) Antibodies to reticulocyte binding protein-like homologue 4 inhibit invasion of Plasmodium falciparum into human erythrocytes. Infect Immun 77: 2427-2435.
47. Biswas S, Dicks MD, Long CA, Remarque EJ, Siani L, et al. (2011) Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1. PLoS One 6: e20977.
48. Goodman AL, Epp C, Moss D, Holder AA, Wilson JM, et al. (2010) New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect Immun 78: 4601-4612.
49. Pandey KC, Singh S, Pattnaik P, Pillai CR, Pillai U, et al. (2002) Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Mol Biochem Parasitol 123: 23-33.
50. Douglas AD, de Cassan SC, Dicks MD, Gilbert SC, Hill AV, et al. (2010) Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28: 7167-7178.
51. Draper SJ, Biswas S, Spencer AJ, Remarque EJ, Capone S, et al. (2010) Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 185: 7583-7595.
52. Bushell KM, Söllner C, Schuster-Boeckler B, Bateman A, Wright GJ, (2008) Large-scale screening for novel low-affinity extracellular protein interactions. Genome Research 18: 622-630.
53. Jossang T, Feder J, Rosenqvist E, (1988) Photon correlation spectroscopy of human IgG. J Protein Chem 7: 165-171.